Thesis
Exploring the immune response to the ChAdOx1 MERS vaccine candidate
- Abstract:
-
Fourteen years after its identification, Middle East respiratory syndrome coronavirus (MERS-CoV) continues to circulate with high case fatality and no licensed vaccines. Key challenges for advancing MERS vaccine development include understanding how different vaccination regimens shape humoral immunity, and elucidating how prior exposure to other coronaviruses influences these immune responses.
This thesis characterises the humoral immune response to the chimpanzee adenovirus Oxford 1 (ChAdOx1)–based MERS vaccine candidate, alongside supporting cellular responses, using clinical trial samples collected before and after the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to examine how exposure to other coronaviruses influences responses to ChAdOx1 MERS, alongside cross-sectional analyses of the relationship between ChAdOx1 MERS responses and immunity to other coronaviruses. In parallel, pre-clinical studies evaluate humoral and cellular immune responses across different vaccination strategies incorporating ChAdOx1 MERS and Modified Vaccinia Ankara–based MERS (MVA-MERS-S) vaccine candidates to inform optimal MERS vaccine regimens.
In the first half of the thesis, I evaluate data from pre- and post-pandemic trials. Different doses were evaluated in pre-pandemic trials in the UK and Saudi Arabia; higher doses induced stronger peak antibody titres, whereas medium doses sustained responses with a stepwise increase in avidity. Baseline immunity to seasonal coronaviruses influenced the magnitude and antigenic targeting of the IgG response. A post-pandemic trial in a predominantly older cohort revealed further evidence of imprinting, with hybrid immunity enhancing spike-specific responses and baseline SARS-CoV-2 immunity augmenting MERS vaccine immunogenicity. However, prior immunisation with ChAdOx1 nCoV-19 was associated with reduced transgene-specific responses to ChAdOx1 MERS, consistent with anti-vector immunity.
The second half of the thesis uses a design of experiments (DoE) approach to evaluate heterologous MERS vaccination strategies in preclinical models, using different combinations of MVA-MERS-S and ChAdOx1 MERS vaccine candidates. Modelling outputs indicated that an MVA-MERS-S prime/ChAdOx1 MERS boost enhanced immune responses compared to the opposite vaccination order. Booster dose was the strongest determinant of immunogenicity; prime dose and interval length shaped epitope specificity. DoE-guided optimisation identified dose–interval combinations suitable for rapid reactive vaccination, as well as longer-interval regimens for proactive immunisation.
Together, these studies advance understanding of MERS vaccine immunogenicity across preclinical and clinical settings, and provide insights that may inform continued clinical development of MERS-CoV vaccine candidates.
Actions
Authors
Contributors
+ Gilbert, S
- Institution:
- University of Oxford
- Division:
- MSD
- Department:
- NDM
- Role:
- Supervisor
- ORCID:
- 0000-0002-6823-9750
+ Kenneil, R
- Institution:
- University of Oxford
- Division:
- MSD
- Department:
- NDM
- Role:
- Supervisor
+ Lambe, T
- Institution:
- University of Oxford
- Division:
- MSD
- Department:
- Paediatrics
- Role:
- Supervisor
- ORCID:
- 0000-0001-7711-897X
+ Angus, B
- Institution:
- University of Oxford
- Division:
- MSD
- Department:
- NDM
- Sub department:
- NDM Strategic
- Role:
- Examiner
- ORCID:
- 0000-0003-3598-7784
+ Daly, J
- Role:
- Examiner
+ King Abdulaziz University
More from this funder
- Funder identifier:
- https://ror.org/02ma4wv74
- Funding agency for:
- Batawi, S
- DOI:
- Type of award:
- DPhil
- Level of award:
- Doctoral
- Awarding institution:
- University of Oxford
- Language:
-
English
- Keywords:
- Deposit date:
-
2026-11-04
- ARK identifier:
Terms of use
- Copyright holder:
- Sarah Batawi
- Copyright date:
- 2025
If you are the owner of this record, you can report an update to it here: Report update to this record